The pharmaceutical industry is growing steadily because input costs are stable compared to other industries and businesses are less affected in a high inflation environment.

Big names in the pharmaceutical industry are wasting no time expanding their market dominance, raising concerns over the marginalisation of private drugstores.

Vietnamese pharmaceutical firms have seen share prices increasing sharply as Covid-19 cases spread with tens of thousands of new infections reported daily.

While Vietnam’s drugmakers are heading to develop new products to increase efficiency and sustain sustainable growth, competition from imported drugs is making their road tougher.

A group of 30 pharmaceutical production companies from India plans to build the first Pharma Park in Vietnam, and Da Nang City’s Hi-tech Park has been suggested as a prime location.

The Vietnamese Government's support for the local pharmaceutical industry will remain steadfast, according to Fitch Solutions.

After months of challenges and faults in the global ingredient supply chain, peaks and valleys are the landscape for Vietnamese drug giants in their first-half performance, 

Pharmaceutical stocks are experiencing an upsurge as fears of coronavirus have boosted demand for healthcare products and services, lifting demand for shares.

Vietnam's pharmaceutical market has a lot of potential coming from the demographics, rising income and priority policies of the government.

VietNamNet Bridge – The pharmaceutical industry should take advantage of traditional medicines, Truong Quoc Cuong, director of the Drug Administration of Viet Nam, told Nong Thon Ngay Nay (Countryside Today) newspaper.

BIDV loans $35m to VSIP Quang Ngai; Ha Noi Stock Exchange to launch new bond products; Import duties on steel to be cut; Investors eye Vietnam wind energy projects; Seafood exporters antsy to make inroads into Russia

VietNamNet Bridge – On March 29, 2013, the Ministry of Health issued Circular No10/2013/TT-BYT amending and supplementing a number of articles of Circular No02/2007/TT-BYT on conditions for the drugs business.